LearnGlossaryMarketStocksSuperinvestorsSign in

BCDA

BioCardia, Inc.

Healthcare · $15M market cap

Verdict

We can't put a fair value on BCDA right now. It looks like a preferred share, note or other security rather than ordinary common stock. The figures we receive belong to the parent company, so they can't value this security.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth-14.9% a year✗
Equity per share growth-34.7% a year✗
Sales growth1.0% a year✗
Free cash flow growth28.0% a year✓
Return on invested capital-57.7%✗

Follow BCDA

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 3, 2026: 1 open-market purchase worth $872. Why purchases matter

Purchases

Altman Peter

President and CEO · 2026-09-03

Bought

$872

About BioCardia, Inc.

BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works